iRhythm sets $1B revenue target by 2027, reaffirms FY2022 guidance, targets 15% EBITDA margin

iRhythm Holdings, Inc.

Reaffirms FY2022 guidance: revenue $415-420M (29-30% growth), gross margin 68-69%, adjusted EBITDA loss $12.5-17.5M.
Sets 2027 goals: $1B+ revenue (~20% CAGR), gross margin ~73%, adjusted EBITDA margin ~15%.
Plans international expansion to 7 countries; introduces Know Your Rhythm early detection program with Heartbeat Health.
Targets $250M annual gross savings by 2027; expects continued innovation with Zio Monitor and ZEUS system.
Core business driven by cardiology and PCP expansion; served 4M patients with 30% revenue CAGR over 5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.